Short-term antiviral therapy for CH

Short-term antiviral therapy for CHB results in the
suppression of viral replication21,22 and has been asso-
ciated with improvements of liver histology in
randomized clinical trials.23 Treatment for 3 years with
the oral antiviral agent lamivudine has also been
shown to slow the clinical progression of liver disease



in patients with advanced fibrosis and cirrhosis.24
However, in this landmark study, disease progression
was assessed clinically and not histologically, and se-
rum HBV DNA results were not reported. Longer
term histological data exist from studies in nucleoside-
naive CHB patients treated with lamivudine or adefo-
vir.25-27 The emergence of antiviral drug resistance
negatively affected the histological benefits that were
observed with lamivudine, and the impact of resistance
on histological response was not reported in the adefo-
vir studies.

結果 (中文) 1:

短期抗病毒治疗慢性乙型肝炎的结果中抑制病毒 replication21，22 和一直 asso-就是与肝组织学的改善随机临床 trials.23 3 年的治疗与口服抗病毒药物拉米夫定也一直能减缓肝脏疾病的临床进展 在先进的 fibrosis 和 cirrhosis.24 的患者然而，在这项划时代的研究，疾病进展临床上和在组织学上，不评定和 se-朗姆酒的乙型肝炎病毒 DNA 结果并没有报告。更长的时间从研究中核苷类-组织学数据存在的术语天真慢性乙型肝炎患者拉米夫定或 adefo-vir.25-27 抗病毒药物耐药性的出现负面影响被的组织学方面受益观察拉米夫定，与耐药性的影响对组织学反应不报道在 adefo-vir 研究。

結果 (中文) 3:

短期抗病毒治疗慢性乙型肝炎的结果病毒replication21,22抑制和被关联—在肝组织学改善的影响随机临床trials.23治疗3年口服抗病毒药物拉米夫定也被示以减缓肝脏疾病的临床进展在晚期fi纤维化和cirrhosis.24然而，在这一里程碑式的研究中，疾病进展临床和组织学检查，并硒—没有报告的结果。长核苷的研究中存在的长期组织学数据—拉米夫定治疗慢性乙型肝炎患者或adefo天真—vir.25-27抗病毒药物耐药性的出现负面影响组织效益fiTS，用拉米夫定观察，并对耐药的影响组织学反应不在adefo报道—病毒的研究。